Marina Biotech makes organisational changes

Creates the position of executive vice president of r&d

Marina Biotech, a US nucleic acid-based drug discovery and development firm, has made some organisational changes.

Richard Ho has joined the firm in the newly created position of executive vice president, Research and Development.

In addition, Philip Ranker has become interim chief financial officer, replacing Peter Garcia who has resigned from the role to pursue other opportunities.

Barry Polisky has moved from chief scientific officer to distinguished scientist and has become chairman of the firm's Scientific Advisory Panel and Michael Templin has been promoted to the newly created position of senior vice president and chief technology officer.

Finally, Alan Dunton has joined the firm as consulting chief medical officer.

Marina Biotech’s goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies.

You may also like

Research & Development

Drug licensing deals in 2010

Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Research & Development

Marina Biotech acquires RNA assets of Novosom

Buys patent rights to Smarticles technology
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Subscribe now